Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Merck & Co., Inc.    MRK

Delayed Quote. Delayed  - 08/25 10:00:14 pm
62.32 USD   -0.65%
08/25 INSIDE THE FDA : Frontrunners Merck & Co., Inc. (NYSE:MRK), GlaxoSm..
08/23DJDeal for Medivation Is the Latest In a Line of Similar Acquisitio..
08/22DJPfizer's Medivation Deal Latest in Long Line of Similar Acquisiti..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

US Judge Upholds Validity Of Merck's Vytorin Patent

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/28/2012 | 12:03am CEST
   By Peter Loftus 
   Of  
 

A federal judge has upheld the validity of a U.S. patent covering Merck & Co.'s (>> Merck & Co., Inc.) Vytorin cholesterol-lowering drug, which could stave off competing generic copies for several years.

In an opinion released Friday, U.S. District Judge Jose Linares in federal court in Newark, N.J., said a patent for Vytorin was valid and enforceable.

Merck, based in Whitehouse Station, N.J., said in a recent regulatory filing it expects its U.S. exclusivity for Vytorin and a related drug, Zetia, to expire in April 2017.

Mylan Inc. (MYL) had applied for U.S. Food and Drug Administration approval to sell a generic version of Vytorin before its patent protection expired, arguing that the patent was invalid and unenforceable.

Schering-Plough, which was acquired by Merck in 2009, filed a patent-infringement lawsuit against Mylan in late 2009, seeking to block Mylan's product. A trial was held in December 2011, leading to Judge Linares's opinion Friday.

On a conference call with analysts Friday morning, Merck Chief Executive Kenneth Frazier said he was anticipating a favorable decision. "We believe this is a patent that is valid and enforceable," he said.

A Mylan spokeswoman couldn't immediately be reached.

Earlier Friday, Merck reported first-quarter Vytorin sales of $444 million and Zetia sales of $614 million.

Merck previously reached a settlement of patent litigation for Zetia with generics manufacturer Glenmark Pharmaceuticals. The pact will allow Glenmark to sell generic Zetia in December 2016, subject to final regulatory approval.

-By Peter Loftus, Dow Jones Newswires; +1-215-982-5581; peter.loftus@dowjones.com

Stocks mentioned in the article : Merck & Co., Inc.
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MERCK & CO., INC.
08/25 INSIDE THE FDA EBOLA EDITION : Frontrunners Merck & Co., Inc. (NYSE:MRK), GlaxoS..
08/23DJDeal for Medivation Is the Latest In a Line of Similar Acquisitions -- WSJ
08/22DJPfizer's Medivation Deal Latest in Long Line of Similar Acquisitions
08/17 DOW MOVERS : Csco, pfe
08/17 INVESTORSOBSERVER : releases covered-call reports for NVIDIA, Dicks Sporting Goo..
08/11 MERCK : Findings from Merck & Company in the Area of Medicinal Chemistry Reporte..
08/10 MERCK : Amica Mutual Insurance Co Lowers stake in Merck & Co. (MRK)
08/09DJMARKET SNAPSHOT : Stocks March Higher, Buoyed By Health-care, Consumer-staples G..
08/09 DOW MOVERS : Mrk, gs
08/09DJBotox Maker Allergan's Revenue Climbs, but Loss More Than Doubles -- WSJ
More news
Sector news : Pharmaceuticals - NEC
02:13p Foreign seed firms team up to oppose new India GM crop rules
08/25 FTSE retreats as pharma stocks fall
08/25DJStocks Fall as Investors Look to Fed's Jackson Hole Meeting
08/25DJStocks Fall as Investors Look to Fed's Jackson Hole Meeting
08/25DJStocks Fall as Investors Look to Fed's Jackson Hole Meeting -- 3rd Update
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
08/24 Merck Offers Value, Yield, And Reliable Dividends
08/24 Candidate Clinton's harsh comments on high price of Mylan's EpiPen sends biot..
08/23 Ships And Ports Topside For Industrial Sector In August
08/23 Who's Next After Medivation?
08/22 Pfizer Pays Up
Advertisement
Financials ($)
Sales 2016 39 681 M
EBIT 2016 13 578 M
Net income 2016 5 853 M
Debt 2016 4 707 M
Yield 2016 2,97%
P/E ratio 2016 30,25
P/E ratio 2017 20,60
EV / Sales 2016 4,46x
EV / Sales 2017 4,40x
Capitalization 172 328 M
More Financials
Chart MERCK & CO., INC.
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MRK | US58933Y1055 | 4-Traders
Full-screen chart
Technical analysis trends MERCK & CO., INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 65,5 $
Spread / Average Target 5,1%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis Chief Financial Officer & Executive Vice President
Michael A. Rosenblatt Chief Medical Officer & Executive Vice President
Clark Golestani Chief Information Officer & Executive VP
Thomas Henry Glocer Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
MERCK & CO., INC.17.99%173 462
JOHNSON & JOHNSON15.43%324 776
ROCHE HOLDING LTD.-11.47%217 694
NOVARTIS AG-9.62%213 882
PFIZER INC.7.71%211 206
GLAXOSMITHKLINE PLC21.19%106 869
More Results